贝伐单抗与多西他赛联合用于多西他赛预处理的激素难治性前列腺癌：一项2期研究。
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
作者信息
Di Lorenzo Giuseppe, Figg William D, Fossa Sophie D, Mirone Vincenzo, Autorino Riccardo, Longo Nicola, Imbimbo Ciro, Perdonà Sisto, Giordano Antonio, Giuliano Mario, Labianca Roberto, De Placido Sabino
机构信息
Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy.
出版信息
Eur Urol. 2008 Nov;54(5):1089-94. doi: 10.1016/j.eururo.2008.01.082. Epub 2008 Feb 5.
OBJECTIVE
Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure.
METHODS
Twenty highly pretreated patients with HRPC received bevacizumab (10mg/kg) and docetaxel (60mg/m(2)) every 3 wk. All patients had bone metastases and eight had measurable lesions.
RESULTS
Eleven patients (55%) had major prostate-specific antigen (PSA) responses, and 3 (37.5%) had objective responses. Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. The treatment was well tolerated.
CONCLUSIONS
Our results show that the combination of bevacizumab and docetaxel is active and well tolerated. Continued investigation of bevacizumab with cytotoxic chemotherapy is warranted in HRPC.
目的
尽管紫杉烷类药物是转移性激素难治性前列腺癌（HRPC）一线治疗中最有效的药物，但大多数患者在接受基于紫杉烷的治疗时最终仍会病情进展。目前尚无药物被批准用于HRPC的二线治疗，但肿瘤学家的常见标准做法是在多西他赛治疗失败后继续治疗患者。
方法
20例接受过多次治疗的HRPC患者每3周接受贝伐单抗（10mg/kg）和多西他赛（60mg/m²）治疗。所有患者均有骨转移，8例有可测量病灶。
结果
11例患者（55%）出现主要前列腺特异性抗原（PSA）反应，3例（37.5%）出现客观反应。在一线多西他赛后报告PSA下降>50%的同一批患者中记录到7例主要PSA反应。然而，在先前单独对多西他赛无反应的患者中观察到4例主要PSA反应。该治疗耐受性良好。
结论
我们的结果表明，贝伐单抗和多西他赛联合使用具有活性且耐受性良好。有必要在HRPC中继续研究贝伐单抗与细胞毒性化疗的联合应用。
Zotero 插件